|Bid||0.00 x 900|
|Ask||27.50 x 1000|
|Day's Range||27.20 - 27.49|
|52 Week Range||21.75 - 35.90|
|Beta (3Y Monthly)||1.28|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
NASDAQ: MOR) announced today that in its lawsuit against Janssen Biotech and Genmab A/S, the parties have settled the dispute. On April 4, 2016 MorphoSys had filed a lawsuit in the United States (U.S.) District Court of Delaware against Janssen Biotech, and Genmab, A/S for patent infringement of U.S. Patent Number 8,263,746. MorphoSys had sought redress for alleged infringement by Janssen's and Genmab's daratumumab, a CD38-directed monoclonal antibody for the treatment of multiple myeloma.
With only four trading days to go, January is set to be the best month for European shares since December 2016. The Stoxx Europe 600 index dropped 0.4 percent, with almost all the sub groups in the red and basic resources shares jumping the most. MorphoSys AG fell 8 percent as a U.S. court declared some patents invalid.
The Court thus granted a motion for Summary Judgement of invalidity filed by Janssen Biotech and Genmab, A/S against the three patents held by MorphoSys. As a result of this decision, the jury trial scheduled for February 2019 to consider defendants' alleged infringement and the validity of the MorphoSys patents will now not take place.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Jan. 17) Avenue Therapeutics Inc (NASDAQ: ATXI ) BioSpecifics ...
NASDAQ: MOR) announced today that its licensee Janssen Research & Development, LLC (Janssen), has further expanded the clinical development of guselkumab (Tremfya(R)) into ulcerative colitis (UC). Janssen has initiated a proof-of-concept phase 2a clinical trial in patients with moderately to severely active ulcerative colitis (UC), a chronic inflammatory bowel disease.
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / December 17, 2018 / MorphoSys (FSE: MOR; NASDAQ: MOR) Dear Madam/Sir, Please note MorphoSys's financial reporting dates 2019 as follows: Publication of Interim Statement ...
NASDAQ: MOR) announced today that according to the title of a presentation to be held next Wednesday afternoon CET (December 12, 2018) at the upcoming Inflammatory Skin Disease Summit (ISDS) conference in Vienna, Austria, guselkumab [Tremfya(R)] demonstrates superior long-term responses to secukinumab [Cosentyx(R)] at Week 48 in the treatment of moderate to severe psoriasis, as results from the ECLIPSE trial. The presentation title has been published online at the website of the ISDS conference (http://www.isds2018.org/scientific-program). MorphoSys expects that this announcement relates to an upcoming presentation of clinical data from the so called "ECLIPSE" clinical study.
PLANEGG/MUNICH, GERMANY / ACCESSWIRE / December 1, 2018 / MorphoSys AG (FSE: MOR; Prime Standard Segment, MDAX & TecDAX; NASDAQ: MOR) today presented data from the ongoing single-arm phase 2 clinical trial ...
NASDAQ: MOR) announced today that its licensee's affiliate, Janssen Pharmaceutical K.K. (Janssen) reported that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Tremfya(R) (guselkumab) for the treatment of patients with palmoplantar pustulosis who are not responding or are refractory to existing treatments. Palmoplantar pustulosis is a debilitating, chronic skin disease that causes pustules and inflammation to appear mainly on the palms of the hands and soles of the feet, greatly affecting patients' quality of life. According to a press release issued by Janssen on November 21, 2018, Tremfya(R) is the first and only biologic treatment available for the estimated 130,000 patients living with palmoplantar pustulosis in Japan.
Notwithstanding the scanty news flow, biotech stocks came under intense selling pressure last week, pushing the iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) further into the red. Here's a list of ...
PLANEGG / MUNICH, GERMANY / ACCESSWIRE / November 21, 2018 / MorphoSys to Present at Upcoming Investor Conferences MorphoSys AG (FSE: MOR); Prime Standard Segment, MDAX & TecDAX; (NASDAQ: MOR) will present ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 19) Merck & Co., Inc. (NYSE: MRK ) Down In The Dumps (Biotech ...
NASDAQ: MOR) announced today that its licensee Janssen Research & Development, LLC (Janssen) initiated a phase 2 clinical study of guselkumab in patients with moderate to severe hidradenitis suppurativa (HS), a chronic skin disease also known as acne inversa. According to clinicaltrials.gov, the randomized, double-blind study, NOVA, is expected to enroll approximately 180 adult patients with moderate to severe HS and will evaluate the efficacy, safety and tolerability of guselkumab against placebo.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 15) Vapotherm, Inc. (NYSE: VAPO ) Down In The Dumps (Biotech ...
Nov 16 (Reuters) - MorphoSys AG: * DGAP-NEWS: MORPHOSYS AND I-MAB SIGN STRATEGIC PARTNERING AGREEMENT FOR MORPHOSYS'S NOVEL IMMUNO-ONCOLOGY AGENT MOR210 * MORPHOSYS -UNDER TERMS OF AGREEMENT, I-MAB WILL ...
NASDAQ: MOR) and I-Mab Biopharma ("I-Mab"), a biotech company focusing exclusively on innovative biologics in immuno-oncology and autoimmune diseases, jointly announced today that they have entered into an exclusive strategic collaboration and regional licensing agreement for MOR210. MOR210 is MorphoSys's proprietary, preclinical-stage antibody directed against C5aR, which has potential to be developed as an immuno-oncology agent. The agreement deepens the existing partnership between the two companies, building upon the ongoing collaboration on MorphoSys's anti-CD38 antibody MOR202.
-Advancing Proprietary Pipeline; Solid Progress in Partnered Programs -Conference Call and Webcast (in English) to be Held on November 6, 2018, at 2:00pm CET (1:00pm GMT / 8:00am EST) PLANEGG/MUNICH, GERMANY ...
- MOR208 (L-MIND): Interim data from phase 2 L-MIND study of MOR208 plus lenalidomide in 81 patients with relapsed/refractory DLBCL accepted for oral presentation - MOR208 (COSMOS): First data from exploratory ...
NASDAQ: MOR) announced today that, in a press release issued today, its licensing partner GSK reported data from their phase 2 BAROQUE clinical study of GSK3196165 (formerly MOR103) in rheumatoid arthritis (RA). Based on its technological leadership in generating antibodies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 29 are currently in clinical development.
MorphoSys's Licensee Janssen has Reported That New Tremfya (R) (Guselkumab) 3-Year Data Shows Stably Maintained Rates of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis PLANEGG/MUNICH, ...
NASDAQ: MOR) announced today that its licensee Janssen Research & Development, LLC, has initiated a phase 3 clinical trial of guselkumab in pediatric patients suffering from chronic plaque psoriasis. According to clinicaltrials.gov, the trial, PROTOSTAR, is expected to enroll approximately 125 children between 6 and 18 years of age with plaque psoriasis and will evaluate the efficacy, safety and pharmacokinetics of guselkumab against etanercept and placebo.
The following are top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Sept. 17.) Champions Oncology Inc (NASDAQ: CSBR ) Emergent Biosolutions ...
NASDAQ: MOR) today announced an expansion of their existing strategic alliance to include peptide-derived therapeutics. The objective of the alliance is to identify novel, peptide-derived therapeutics for unmet medical needs that will be valuable additions to both companies’ pipelines. This alliance expands the existing partnership of the two companies signed in November 2016 to jointly discover and develop antibody-based therapies in dermatology.
NASDAQ: MOR) today announced an expansion of their existing strategic alliance to include peptide-derived therapeutics. The objective of the alliance is to identify novel, peptide-derived therapeutics for unmet medical needs that will be valuable additions to both companies' pipelines. This alliance expands the existing partnership of the two companies signed in November 2016 to jointly discover and develop antibody-based therapies in dermatology.